Major Depressive Disorder Market

The global Major Depressive Disorder (MDD) market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The USA market for Global Major Depressive Disorder (MDD) market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The China market for Global Major Depressive Disorder (MDD) market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The Europe market for Global Major Depressive Disorder (MDD) market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person's ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.

Major Depressive Disorder Market aims to provide a comprehensive presentation of the global market for Major Depressive Disorder (MDD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Major Depressive Disorder (MDD). Major Depressive Disorder Market contains market size and forecasts of Major Depressive Disorder (MDD) in global, including the following market information:

• Global Major Depressive Disorder (MDD) Market Revenue, 2018-2023, 2024-2030, ($ millions)
• Global top five companies in 2022 (%)

We surveyed the Major Depressive Disorder (MDD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

• Antidepressant Drugs
• SSRIs
• SNRIs
• Benzodiazepines
• Others

• Hospitals
• Clinics
• Others

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
• The Middle East and Africa (Middle East, Africa)
• South and Central America (Brazil, Argentina, Rest of SCA)

• Key companies Major Depressive Disorder (MDD) revenues in global market, 2018-2023 (estimated), ($ millions)
• Key companies Major Depressive Disorder (MDD) revenues share in global market, 2022 (%)

• Pfizer
• GlaxoSmithKline
• Merck
• AstraZeneca
• Eli Lily
• Johnson & Johnson
• Forest Laboratories
• Sanofi-Aventis
• H. Lundbeck
• Bristol-Myers Squibb

Chapter 1: Introduces the definition of Major Depressive Disorder (MDD), market overview.

Chapter 2: Global Major Depressive Disorder (MDD) market size in revenue.

Chapter 3: Detailed analysis of Major Depressive Disorder (MDD) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Major Depressive Disorder (MDD) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: The main points and conclusions of the report.